Total Assets

Declined from $3,087.8M in Q3 2024 to $2,625.7M in Q4 2025 (15% decrease)

In Q3 2024, total assets were buoyed by increases in current assets (e.g., a $15.5M rise in accounts receivable and a buildup in inventories) and modest non-current asset gains. In contrast, by Q4 2025 major asset impairments—including significant write-downs in goodwill and amortization of intangibles—eroded the asset base, resulting in the overall decline. " "

Stockholders’ Equity

Dropped from $1,463.2M in Q3 2024 to $1,051.9M in Q4 2025 (28% decrease)

While Q3 2024 benefited from a modest net income of $9.8M plus cash benefits from stock-based compensation and foreign currency gains, FY 2025 was hit hard by a $304.9M net loss, substantial impairment charges, and increased other comprehensive losses. These factors sharply reduced retained earnings and equity despite some offsetting capital contributions. " "

Goodwill

Fell from $412.5M in Q3 2024 to $96.7M in Q4 2025 (approximately 76% decline)

In Q3 2024, goodwill saw only minor increases driven by a $4.8M foreign currency translation adjustment. However, by Q4 2025 the company recorded a $294.0M impairment charge for the non-healthcare segment, effectively eliminating most of the previous goodwill balance. " " "

Inventories

Decreased from $569.9M in Q3 2024 to $459.2M in Q4 2025 (nearly 19% drop)

Q3 2024 reflected an inventory buildup—especially in finished goods (an increase of $23.9M)—likely in anticipation of future demand. By Q4 2025, a reduction in production or a response to softer sales led to a contraction in inventories, reversing the earlier buildup. " "

Trade Accounts Receivable

Increased from $371.0M in Q3 2024 to $411.3M in Q4 2025 (around 11% growth)

The prior period saw a modest increase in receivables partly due to an upturn in related party balances. In Q4 2025, continued growth in credit sales contributed further to the rising balance, reflecting ongoing revenue expansion even as other metrics declined. " "

Cash and Cash Equivalents

Rose from $158.5M in Q3 2024 to $177.6M in Q4 2025 (approximately 12% increase)

Despite some withdrawals previously from operating and investing activities, by Q4 2025 improved operating cash flows, effective working capital management, and favorable foreign exchange adjustments combined to boost cash reserves, enhancing the company’s liquidity position relative to the prior period. " "